Active Humoral Response Reverts Tumorigenicity through Disruption of Key Signaling Pathway
Immune checkpoint inhibitors such as monoclonal antibodies (mAbs) are amongst the most important breakthroughs in cancer therapeutics. However, high cost and short acting time limits its affordability and clinical application. Therefore, an economical and durable alternative is urgently needed. Prev...
Zapisane w:
| Główni autorzy: | , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
MDPI AG
2022-01-01
|
| Seria: | Vaccines |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.mdpi.com/2076-393X/10/2/163 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|